Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial

View Full Paper
Ask AI
Bookmark
Share

Authors

ZZZeping ZhouHLHeng LiPGPengxiang Guo

Discussion

Loading...

Member takes

Overview

Randomized controlled trial improved CR and MRD negativity in elderly AML patients, suggesting DEC3-VEN is a better option for induction therapy.

Key Points

  • DEC3-VEN improved complete response rate of 73.1% compared to 52.9% with VEN+AZA in elderly AML patients.
  • The study included 120 patients, with significant differences in MRD negativity rates observed (77.5% vs. 51.6%).
  • Multicenter randomized controlled trial registered on ClinicalTrials.gov examined the effects on event-free survival.
  • Results indicate DEC3-VEN may offer better initial treatment outcomes for elderly AML patients, needing further validation.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d38ehttps://doi.org/10.1182/blood-2025-3450
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial2025
  2. 2Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS2025
  3. 3Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India2025
  4. 4Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia2025 · 1 citations
  5. 5Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion2025 · 1 citations